200 related articles for article (PubMed ID: 24869579)
1. New approved indication for ibrutinib.
Aschenbrenner DS
Am J Nurs; 2014 Jun; 114(6):21. PubMed ID: 24869579
[No Abstract] [Full Text] [Related]
2. Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Mazzucchelli M; Cairoli R; Montillo M
Future Oncol; 2018 Apr; 14(8):681-697. PubMed ID: 29243946
[TBL] [Abstract][Full Text] [Related]
3. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
Spaargaren M; de Rooij MF; Kater AP; Eldering E
Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
Christoforidou A; Kapsas G; Bezirgiannidou Z; Papamichos S; Kotsianidis Ι
Turk J Haematol; 2018 May; 35(2):147-149. PubMed ID: 29391330
[No Abstract] [Full Text] [Related]
5. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
Wang M; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):245-9. PubMed ID: 24598688
[TBL] [Abstract][Full Text] [Related]
6. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib resistance in chronic lymphocytic leukemia.
Furman RR; Cheng S; Lu P; Setty M; Perez AR; Guo A; Racchumi J; Xu G; Wu H; Ma J; Steggerda SM; Coleman M; Leslie C; Wang YL
N Engl J Med; 2014 Jun; 370(24):2352-4. PubMed ID: 24869597
[No Abstract] [Full Text] [Related]
8. Ibrutinib-associated T-cell pseudolymphoma.
Ho AKH; Koh XQ; Liau MMQ; Tan KB; Tan CL
Clin Exp Dermatol; 2019 Oct; 44(7):828-830. PubMed ID: 30623454
[No Abstract] [Full Text] [Related]
9. A new era of treatment for chronic lymphocytic leukaemia?
Brown JR
Lancet Oncol; 2014 Jan; 15(1):3-5. PubMed ID: 24332240
[No Abstract] [Full Text] [Related]
10. A mechanism-driven treatment for chronic lymphocytic leukemia?
Foà R; Guarini A
N Engl J Med; 2013 Jul; 369(1):85-7. PubMed ID: 23782159
[No Abstract] [Full Text] [Related]
11. B-cell receptor inhibitors in chronic lymphocytic leukemia.
Flinn IW
Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
[No Abstract] [Full Text] [Related]
12. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
Wanquet A; Birsen R; Lemal R; Hunault M; Leblond V; Aurran-Schleinitz T
Blood; 2016 May; 127(19):2356-8. PubMed ID: 26994148
[No Abstract] [Full Text] [Related]
13. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Tran PN; O'Brien S
Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
[TBL] [Abstract][Full Text] [Related]
14. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
[No Abstract] [Full Text] [Related]
15. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
Famà R; Bomben R; Rasi S; Dal Bo M; Ciardullo C; Monti S; Rossi F; D'Agaro T; Zucchetto A; Gattei V; Gaidano G; Rossi D
Blood; 2014 Dec; 124(25):3831-3. PubMed ID: 25498455
[No Abstract] [Full Text] [Related]
17. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Kaur V; Swami A
Ann Hematol; 2017 Jul; 96(7):1175-1184. PubMed ID: 28342031
[TBL] [Abstract][Full Text] [Related]
19. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
20. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
